Literature DB >> 2889408

Evaluation of enzymes in serum and cerebrospinal fluid in cases of cerebrovascular accidents.

N Nand1, S Gupta, M Sharma, S N Khosla, A S Saini, H Lal.   

Abstract

Gamma glutamyl transpeptidase (GGTP), glutamic oxaloacetic transaminase (GOT), and glutamic pyruvic transaminase (GPT) were measured serially in the serum and cerebrospinal fluid (CSF) of 22 patients with fresh stroke and an equal number of age- and sex-matched healthy control subjects. It was observed that levels of these enzymes in the CSF of control subjects were very low but were significantly elevated (p less than 0.001) in both serum and CSF in patients with stroke. The elevation was greater in the CSF than in the serum and was maximum during the first four days of stroke. Thereafter, the enzymatic activity declined. Of all these enzymes, GGTP in CSF correlated best with the clinical picture. It was possible to differentiate between the ischemic and hemorrhagic type of stroke on the basis of CSF levels of GGTP (greater than 60.0 units in hemorrhagic stroke). There was no correlation between GGTP levels in CSF and serum or among GOT, GPT, and GGTP in CSF. It can be concluded, therefore, that estimation of GGTP in CSF is helpful not only in predicting the degree of cerebral damage and functional outcome of the patient following stroke but also in differentiating the type of stroke.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889408     DOI: 10.1177/000331978703801004

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

1.  Is serum gamma-glutamyl transferase a good marker of alcohol intake in stroke patients?

Authors:  K Peck; R Shinton; G Beevers
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

2.  Changes of liver enzymes and bilirubin during ischemic stroke: mechanisms and possible significance.

Authors:  Antonio Muscari; Andrea Collini; Elisa Fabbri; Marco Giovagnoli; Chiara Napoli; Valentina Rossi; Luca Vizioli; Andrea Bonfiglioli; Donatella Magalotti; Giovanni M Puddu; Marco Zoli
Journal:  BMC Neurol       Date:  2014-06-06       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.